SCHEMBL6431971

SCHEMBL6431971

COc1cccc(C(=NN)c2nc3nonc3nc2Nc2ccc(Cl)c(Cl)c2)c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
TP53 P04637 3/20 0.39
CCR2 P41597 1/20 0.39
CCR5 P51681 1/20 0.39
EPHA2 P29317 10/20 0.38
KDR P35968 9/20 0.38
KLK1 P06870 1/20 0.37
KLK5 Q9Y337 1/20 0.37
KLKB1 P03952 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
POLB P06746 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HTT P42858 1/20 0.35
EPHB4 P54760 7/20 0.35
ERBB2 P04626 4/20 0.35
CSF1R P07333 1/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6431950 0.92 MAPT (0.43) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL6417908 0.90 TNF (0.40) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL6436233 0.87 SMN1; SMN2 (0.42) MAPTSMN1; SMN2TP53KLK1KLK5
SCHEMBL6419556 0.87 KMT2A (0.38) MAPTSMN1; SMN2TP53KLK1KLK5
SCHEMBL6419567 0.87 KMT2A (0.38) MAPTSMN1; SMN2TP53KLK1KLK5
SCHEMBL6417043 0.84 SMN1; SMN2 (0.38) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL6432241 0.83 SMN1; SMN2 (0.38) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL6413509 0.80 EGFR (0.38) KDREPHB4ERBB2CSF1REGFR
SCHEMBL6416050 0.80 TNF (0.38) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL6414171 0.80 DHODH (0.44) MAPTSMN1; SMN2TP53CCR2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885SMN1; SMN2 4369/4885TP53 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.